Amaro
Novel taste receptor therapeutics for metabolic disease
New York, United States · Founded 2021
- Headquarters
- New York
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- amarotx.com
- Last Round
- SeedJan 2019
- Rounds
- 1
About
Amaro Therapeutics is a clinical-stage biotech company founded in 2021 and based in New York. The company develops first-in-class small molecule therapeutics targeting bitter taste receptors (TAS2R) for the treatment of metabolic and immunologic diseases. Amaro's proprietary platform leverages a novel understanding of TAS2R biology to create oral, tissue-selective medicines addressing significant patient unmet needs in obesity, diabetes, and immune-mediated conditions.
Summary
Amaro is an Adtech company based in New York, United States, founded in 2021. Its most recent funding was a Seed round in Jan 2019.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2019
Similar Companies
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...
Databricks is the pioneer of the data lakehouse, a unified platform for data science, machine lea...
AI compute infrastructure platform backed by NVIDIA.